This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Xofigo Banner

Xofigo®(radium-223 dichloride)

Dosing and Administration

Xofigo IV injection

Xofigo has a fixed course of treatment

Treat for all 6 cycles of Xofigo to maximise overall survival benefit

  • Xofigo is administered as a 1-minute IV injection every 4 weeks for 6 injections.
  • Standard bloodwork required prior to every dose.

Help your patients experience the benefits of Xofigo

3.6 months

SIGNIFICANTLY EXTENDED MEDIAN OS BY 3.6 MONTHS VS PLACEBO

5.8 months

XOFIGO A PROLONGED TIME TO FIRST SSE BY 5.8 MONTHS VS PLACEBO

QoL

SLOWER DECLINE IN QoL WHILE ON TREATMENT VS PLACEBO

Use of Xofigo is not recommended in patients with low levels of osteoblastic bone metastases.

Abbreviations

OS,
overall survival;
SSE,
 symptomatic skeletal event;
QoL,
 quality of life.

 

PP-XOF-IE-0131-1   |   February 2026

 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.

    • 1
      Xofigo®(radium-223 dichloride): Summary of Product Characteristics.
    • 2
      Shore ND. Urology. 2015;85(4):717-724.
    • 3
      Parker C, et al. N Engl J Med. 2013;369(3):213-223.
    • 4
      Nilsson S, et al. Ann Oncol. 2016;27(5):868-874.
    • 5
      Parker C, et al. Prostate Cancer Prostatic Dis. 2018;21(1):37-47.